Evidence map›Paper›PMID 39881254›Full record

ArticleMolecular medicine (Cambridge, Mass.)2025

Tegaserod maleate exerts anti-tumor effects on prostate cancer via repressing sonic hedgehog signaling pathway.

Maoping Cai, Shengdong Ge, Yaying Hong, Yao Chen, Yang-Zi Ren, Dacai Zhong, Mingkun Chen, Yuan Liu, Zhe-Sheng Chen, Ninghan Feng and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Maoping Cai *Department of Urology, The Fifth Affiliated Hospital of Southern Medical University, Guangzhou, 510920, Guangdong, People's Republic of China.
Shengdong Ge *Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, People's Republic of China.
Yaying Hong *Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, People's Republic of China.
Yao ChenCollege of Pulmonary and Critical Care Medicine, The 8th Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Yang-Zi RenDepartment of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong, People's Republic of China.
Dacai ZhongZhanjiang Institute of Clinical Medicine, Central People's Hospital of Zhanjiang, Zhanjiang, 524045, Guangdong, People's Republic of China.
Mingkun ChenThe Third Clinical College, Southern Medical University, Guangzhou, 510630, Guangdong, People's Republic of China.
Yuan LiuDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, People's Republic of China.
Zhe-Sheng ChenDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, 11439, USA.
Ninghan FengDepartment of Urology, Jiangnan University Medical Center, Wuxi, 214002, People's Republic of China. fnh888@njmu.edu.cn.
Zhanghui ChenZhanjiang Institute of Clinical Medicine, Central People's Hospital of Zhanjiang, Zhanjiang, 524045, Guangdong, People's Republic of China. zjcell@126.com.
Shan-Chao ZhaoDepartment of Urology, The Fifth Affiliated Hospital of Southern Medical University, Guangzhou, 510920, Guangdong, People's Republic of China. lulululu@smu.edu.cn.ORCID 0000-0002-1162-8077

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2022A1515010437National Key Research and Development Program of China 2023YFE0204500National Natural Science Foundation of China 82272856President's Foundation of the Third Affiliated Hospital of Southern Medical University YM2021010
6 · The paper itself

Abstract

Prostate cancer (PCa) is a highly common type of malignancy and affects millions of men in the world since it is easy to recur or emerge therapy resistance. Therefore, it is urgent to find novel treatments for PCa patients. In the current study, we found that tegaserod maleate (TM), an FDA-approved agent, inhibited proliferation, colony formation, migration as well as invasion, caused the arrest of the cell cycle, and promoted apoptosis of PCa cells in vitro. In addition, TM suppressed the tumor growth in the cell-derived xenograft (CDX) mouse model in vivo. Mechanistically, TM exerted anti-tumor effects via downregulating GLI2, and its downtream targets, thus inhibiting the sonic hedgehog (SHH) signaling pathway. In brief, our findings demonstrated that TM effectively inhibited the activities of PCa cells by suppressing the SHH signaling pathway and provided a potential new agent for the treatment of PCa.

Indexed as

Hedgehog ProteinsIndolesProstatic NeoplasmsSerotonin Receptor AgonistsAnimalsCell Line, TumorCell ProliferationDown-RegulationDrug RepositioningGene Expression Regulation, NeoplasticHumansMaleMiceMice, NudeNuclear ProteinsSignal TransductionGLI2 protein, humanHedgehog ProteinsIndolesNuclear ProteinsSerotonin Receptor AgonistsSHH protein, humantegaserodZinc Finger Protein Gli2GLI2Prostate cancer (PCa)Sonic hedgehog (SHH) signalingTegaserod maleate (TM)Treatment

Identifiers

PMID39881254
PMCPMC11780919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.